ERBB2 and breast carcinoma: Interim data revealed the ORR of HR+/HER2- breast cancer cohort and TNBC cohort were 26.8% (95% CI, 14.2 ∼ 42.9) and 31.8% (95% CI, 18.6 ∼ 47.6) respectively; while the ORR of topo I-naive subgroup in TNBC cohort was 40.0% (95% CI, 22.7 to 59.4).